Dr. Richard Amerling MD
Associate Professor of Clinical Medicine, Albert Einstein College of Medicine
Member of the Healthcare Council
Council Member Biography
Richard Amerling, MD, is Director of Outpatient Dialysis and Continuous Renal Replacement Therapy at Beth Israel Medical Center in New York City. He is also an Associate Professor of Clinical Medicine at Albert Einstein College of Medicine as well as a Director of the Association of American Physicians and Surgeons. Dr. Amerling has an extensive background in all aspects of consultative nephrology, including hypertension, kidney stones, glomerular diseases, diabetes, renal biopsy, and acute and chronic renal failure. He has written extensively about health care economics and politics and has been published in the New York Times, The Wall Street Journal, Investor's Business Daily, The National Review, Internal Medicine News, The Dialysis Times, and Nephrology News and Issues. (This is me - Update Profile)
Employment History
- 2007 - Unspecified
- Associate Professor of Clinical Medicine, Albert Einstein College of Medicine
- 1990 - Unspecified
- Director of Outpatient Dialysis, BETH ISRAEL MEDICAL CENTER
GLG NewsSM Analyses by Richard Amerling
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
July 25, 2008
Drugs to Build Bones May Weaken Them | www.nytimes.com
Considering the effects of fosamax and other bisphosphonates on bone remodeling, it is not at all surprising to see problems arising with the long term use of these agents.
-
So Much for Health "Insurance"
July 10, 2008
Pricey Drugs Put Squeeze on Doctors | online.wsj.com
It's intresting that nowhere in this article was the topic of true insurance for catastrophic illness brought up. The problem with our current health insurance market is that for most it is pre-paid care, not insurance against a rare, but catastrophic, event.
-
Our Kids on Statins...........Not!
July 10, 2008
8-Year-Olds on Statins? A New Plan Quickly Bites Back | www.nytimes.com
With the pipeline for new drugs running dry, it is no surprise that pharmaceutical companies are looking to expand indications for existing products still under patent protection. What better way to do this than by creating entirely new patient populations out of whole cloth?
GLG Study Groups with Richard Amerling(?)
| Study Group Name | No. Members |
|---|---|
| Managed Care Experts | 733 |
| Medicare Experts | 570 |
| Nephrologists (US) | 537 |
| Attending-level Nephrologists (US) | 267 |
| Formulary Design Experts | 259 |
GLG Live Meetings with Richard Amerling(?)
Richard Amerling has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.